Literature DB >> 22690083

Aberrant methylation and downregulation of sall3 in human hepatocellular carcinoma.

Xue-Xi Yang1, Jing-Zhe Sun, Fen-Xia Li, Ying-Song Wu, Hong-Yan Du, Wei Zhu, Xiang-Hong Li, Ming Li.   

Abstract

AIM: To investigated whether sall3 transcription was regulated by promoter CpG island hypermethylation in hepatocellular carcinoma (HCC).
METHODS: The cell lines Huh7, HepG2, SK-HEP1, SMMC7721, Bel7402, QGY7703 and a cohort of 38 HCC tissue specimens and corresponding nontumorous tissues were subjected to analysis for sall3 promoter CpG island methylation and mRNA transcription. sall3 promoter CpG island methylation levels were determined using the MassARRAY platform and mRNA transcription levels of the gene were detected by quantitative real-time polymerase chain reaction.
RESULTS: The levels of sall3 mRNA were decreased by more than twofold in 33 of 38 tumor tissues compared to adjacent noncancerous tissues. Among these 33 tumor tissues with lower levels of sall3 mRNA, 24 showed higher levels of methylation. Based on these results, we hypothesized that the decrease in sall3 mRNA transcription level was likely due to promoter CpG island hypermethylation. Changes in sall3 mRNA transcription and promoter CpG island methylation were determined in the above six cell lines after treatment with 0, 0.1, 0.5 and 2.5 μmol 5-aza-2-deoxycytidine, a demethylating agent. Promoter CpG island methylation levels decreased in a dose-dependent manner in all six cell lines, while the mRNA transcription level increased dose-dependently in Huh7, HepG2, SK-HEP1 and SMMC7721 cells and irregularly in Bel7402 and QGY7703 cells.
CONCLUSION: These results indicated that promoter CpG island hypermethylation contributes to the downregulation of sall3 mRNA transcription in HCC.

Entities:  

Keywords:  Aberrant methylation; Down regulation mRNA transcription; Hepatocellular carcinoma; sall3

Mesh:

Substances:

Year:  2012        PMID: 22690083      PMCID: PMC3370011          DOI: 10.3748/wjg.v18.i21.2719

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma.

Authors:  Toyoki Moribe; Norio Iizuka; Toshiaki Miura; Naoki Kimura; Shigeru Tamatsukuri; Hideo Ishitsuka; Yoshihiko Hamamoto; Kazuhiko Sakamoto; Takao Tamesa; Masaaki Oka
Journal:  Int J Cancer       Date:  2009-07-15       Impact factor: 7.396

Review 3.  Chromatin, cancer and drug therapies.

Authors:  Connie C Cortez; Peter A Jones
Journal:  Mutat Res       Date:  2008-07-22       Impact factor: 2.433

Review 4.  Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery.

Authors:  A Ganesan; L Nolan; S J Crabb; G Packham
Journal:  Curr Cancer Drug Targets       Date:  2009-12       Impact factor: 3.428

5.  Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake.

Authors:  Marie-Pierre Lambert; Anupam Paliwal; Thomas Vaissière; Isabelle Chemin; Fabien Zoulim; Massimo Tommasino; Pierre Hainaut; Bakary Sylla; Jean-Yves Scoazec; Jörg Tost; Zdenko Herceg
Journal:  J Hepatol       Date:  2010-09-25       Impact factor: 25.083

Review 6.  The fundamental role of epigenetic events in cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Nat Rev Genet       Date:  2002-06       Impact factor: 53.242

Review 7.  The continuing challenge of hepatic cancer in Asia.

Authors:  E C H Lai; W Y Lau
Journal:  Surgeon       Date:  2005-06       Impact factor: 2.392

Review 8.  Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.

Authors:  Augusto Villanueva; Beatriz Minguez; Alejandro Forner; Maria Reig; Josep M Llovet
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

9.  A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer.

Authors:  Jian Yu; Tongyu Zhu; Zhirou Wang; Hongyu Zhang; Ziliang Qian; Huili Xu; Baomei Gao; Wei Wang; Lianping Gu; Jun Meng; Jina Wang; Xu Feng; Yixue Li; Xuebiao Yao; Jingde Zhu
Journal:  Clin Cancer Res       Date:  2007-12-15       Impact factor: 12.531

10.  Head and tail development of the Drosophila embryo involves spalt, a novel homeotic gene.

Authors:  G Jürgens
Journal:  EMBO J       Date:  1988-01       Impact factor: 11.598

View more
  6 in total

1.  Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study.

Authors:  Erin M Siegel; Steven Eschrich; Kathryn Winter; Bridget Riggs; Anders Berglund; Abidemi Ajidahun; Jeff Simko; Jennifer Moughan; Jaffer Ajani; Anthony Magliocco; Abul Elahi; Sarah Hoffe; David Shibata
Journal:  Dis Colon Rectum       Date:  2014-08       Impact factor: 4.585

2.  A functional variant of NEDD4L is associated with obesity and related phenotypes in a Han population of Southern China.

Authors:  Yu-Lin Wang; Hui-Ying Liang; Yun-He Gao; Xue-Ji Wu; Xi Chen; Bing-Ying Pan; Xue-Xi Yang; Hua-Zhang Liu
Journal:  Int J Mol Sci       Date:  2013-04-02       Impact factor: 5.923

3.  Aberrant Hypermethylation of SALL3 with HPV Involvement Contributes to the Carcinogenesis of Cervical Cancer.

Authors:  Xing Wei; Shaohua Zhang; Di Cao; Minyi Zhao; Qian Zhang; Juan Zhao; Ting Yang; Meili Pei; Li Wang; Yang Li; Xiaofeng Yang
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

4.  Epigenetic silencing of SALL3 is an independent predictor of poor survival in head and neck cancer.

Authors:  Kiyoshi Misawa; Daiki Mochizuki; Atsushi Imai; Yuki Misawa; Shiori Endo; Masato Mima; Hideya Kawasaki; Thomas E Carey; Takeharu Kanazawa
Journal:  Clin Epigenetics       Date:  2017-06-12       Impact factor: 6.551

5.  Epigenetic modification of SALL1 as a novel biomarker for the prognosis of early stage head and neck cancer.

Authors:  Kiyoshi Misawa; Yuki Misawa; Atsushi Imai; Daiki Mochizuki; Shiori Endo; Masato Mima; Ryuji Ishikawa; Hideya Kawasaki; Takashi Yamatodani; Takeharu Kanazawa
Journal:  J Cancer       Date:  2018-02-28       Impact factor: 4.207

Review 6.  SALL Proteins; Common and Antagonistic Roles in Cancer.

Authors:  Claudia Álvarez; Aracelly Quiroz; Diego Benítez-Riquelme; Elizabeth Riffo; Ariel F Castro; Roxana Pincheira
Journal:  Cancers (Basel)       Date:  2021-12-15       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.